


FACT SHEET As of October, 2022



We're an agile pharmaceutical company dedicated to simplifying access to life-changing medicine, for good. We provide easy access to fairly-priced medicines through robust manufacturing, consistent supply, and rapid response to your needs, so you can spend your time focusing on your patients.




- Global network of **FDA approved manufacturing** and R&D partners in Europe, India and China
- Strategic partnerships with proven track record of successfully taking new drugs to market

Suite of capabilities with robust manufacturing and R&D


Experienced leadership team with **strong** quality and compliance expertise overseeing **75 employees**

Deep acute channel expertise and customer relationships, with **hospital-based sales force**

A BLUEPRINT FOR SUCCESS



2021-22 REVENUE



Meitheal continues to invest in further developing and expanding each therapeutic category

APPROXIMATELY 50% INCREASE IN PORTFOLIO SIZE OVER NEXT THREE YEARS*

2022 NUMBER OF PRODUCTS

17 -----48 18 6 7 2025 NUMBER OF PRODUCTS 31 22 11 7 **Critical Care** Oncology Anesthesia Anti-Infectives

(*based on number of molecules in MH portfolio)

Achieved over of our launched market molecules (based on IQVIA September 2022 data)

Achieved (based on IQVIA unit volume September 2022)



OUR PURPOSE

NUR

Simplify access to life-changing medicine, for good. Healthcare solutions within reach.

OUR MISSION

We solve healthcare challenges by building authentic relationships, providing innovative, value-based solutions, and keeping our promises.

OUR VALUE PROPOSITION

Spend more time focusing on your patients. With Meitheal as your partner, you have access to fairly priced, essential medicines - and peace of mind.

meitheal

www.meithealpharma.com

The brand names mentioned here are the trademarks of their respective owners. ©2022 Meitheal Pharmaceuticals. All rights reserved.